Method for purifying semaglutide intermediate with surfactant

By using polystyrene/divinylbenzene reversed-phase packing material for the purification of semaglutide intermediates, the problems of low purity and recovery rate in existing technologies have been solved, achieving high-efficiency purification and reducing costs.

CN119019531APending Publication Date: 2024-11-26SUZHOU SEPAX TECHNOLOGIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411371938.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the existing technology, the purification methods for semaglutide intermediates suffer from low sample purity and low recovery rate. In particular, when using surfactants, conventional hydrophobic chromatography schemes cannot be effectively optimized, resulting in poor purity and recovery rate, and the cost of reversed-phase packing is high.

Method used

A reversed-phase packing material based on highly cross-linked polystyrene/divinylbenzene (PS/DVB) was used as the stationary phase. Combined with gradient elution of ammonium formate solution and acetonitrile, the purification steps were simplified. The ionization properties of surfactants were utilized to avoid their interference with the purification process, thereby improving purity and recovery rate.

Benefits of technology

This study improved the purity of the semaglutide intermediate from about 90% to 95-99%, increased the recovery rate from about 83% to 95-100%, and reduced production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005067810460000043
    Figure BDA0005067810460000043
  • Figure BDA0005067810460000051
    Figure BDA0005067810460000051
  • Figure BDA0005067810460000062
    Figure BDA0005067810460000062
Patent Text Reader

Abstract

The invention discloses a purification method of a semaglutide intermediate with a surfactant, and belongs to the field of purification methods of biomacromolecules. Comprising the following steps: 1, filtering a semaglutide intermediate crude product to obtain a filtrate; 2, taking the filtrate obtained in the step 1, taking a reverse-phase filler PolyRP-300 with a high-crosslinking-degree polystyrene / divinyl benzene material as a matrix as a stationary phase, taking an ammonium formate solution as a mobile phase A and taking acetonitrile as a mobile phase B, carrying out gradient elution, and collecting a fraction solution; step 3, carrying out purity analysis on the fraction solution in the step 2; and 4, combining the fraction solutions with the purity greater than 95% in the step 3, and detecting the purity and the recovery rate. The gradient of the gradient elution in the step 2 is 5-10 minutes, and the time spent on stepping 1% gradient and 20-40% gradient is 100-200 minutes. The purification method of the semaglutide intermediate with the surfactant, provided by the invention, can achieve the effects of simple operation steps, high sample purity and high recovery rate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a method for purifying biomacromolecules, in particular to a method for purifying a semaglutide intermediate with a surfactant. Background Art

[0002] Semeglutide, developed by Novo Nordisk, is a novel, long-acting GLP-1 analog. It is a long-acting dosage form developed based on the basic structure of liraglutide. The basic dosing frequency is maintained at once a week. It has a significant therapeutic effect on blood sugar control in patients with type 2 diabetes.

[0003] At present, the fermentation expression of semaglutide intermediates is mostly intracellular soluble expression, with low expression level, which is not conducive to industrial scale-up; the expression level of inclusion body expression is high, but due to the complexity of the reagents used for renaturation, the sample concentration is too high after enzyme cleavage, which makes the sample easy to aggregate and precipitate. Therefore, the use of stabilizer-surfactant is introduced in the process of fermentation inclusion body expression. On the one hand, surfactants can inhibit the formation of aggregates, increase the stability of samples at high concentrations, and reduce the sample volume; on the other hand, it reduces the impact of complex reagents on sample stability during renaturation.

[0004] However, due to the effect of the introduced surfactant on the hydrophobic force, the conventional purification scheme of semaglutide intermediates, hydrophobic chromatography, cannot be optimized according to the normal process, resulting in the final purity and recovery rate being inferior to the results of intracellular soluble expression.

[0005] In the prior art, the purification scheme of semaglutide intermediates containing surfactants has a sample purity of only about 90% and a recovery rate of only about 83%. In addition, in the prior art, a silica-based reverse-phase filler bonded with octyl or octadecyl is usually used, and the cost of such reverse-phase fillers is relatively high. Summary of the invention

[0006] Purpose of the invention: The purpose of the present invention is to provide a method for purifying a semaglutide intermediate with a surfactant, which has simple operating steps, cost savings, high sample purity and high recovery rate.

[0007] Technical solution: The method for purifying the semaglutide intermediate with a surfactant of the present invention comprises the following steps:

[0008] Step 1: filtering the crude semaglutide intermediate to obtain a filtrate;

[0009] Step 2: Take the filtrate obtained in step 1, use the reverse phase filler as the stationary phase, ammonium formate solution as the mobile phase A, and acetonitrile as the mobile phase B, perform gradient elution on the filtrate, and collect the fraction solution;

[0010] Step 3: Conducting purity analysis on the fraction solution in step 2;

[0011] Step 4: Combine the fraction solution samples with a purity greater than 95% in step 3, and test the purity and recovery rate. The resulting combined sample is the purified sample of the semaglutide intermediate.

[0012] Preferably, the reverse phase filler in step 2 is based on a highly cross-linked polystyrene / divinylbenzene material.

[0013] Preferably, the particle size of the reverse phase filler in step 2 is 10 μm and the pore size is

[0014] Preferably, the molar concentration of the ammonium formate solution in step 2 is 20-50 mmol / L, which may be but is not limited to 20 mmol / L, 30 mmol / L, 40 mmol / L, 50 mmol / L, and is preferably 30 mmol / L.

[0015] Preferably, the pH of the ammonium formate solution in step 2 is 7-8, which may be, but is not limited to, 7.0, 7.3, 7.4, 7.5, 7.6, 7.8, 8.0, preferably 7.5.

[0016] Preferably, the gradient elution in step 2 has a slope of 5 to 10 min with a step of 1%; the time taken for a 20-40% gradient is 100 to 200 min.

[0017] Preferably, in step 2, the fractions collected include fractions whose signal values ​​rise to 500 mAU and fall to 500 mAU under monitoring at 280 nm.

[0018] Preferably, the crude product preparation method described in step 1 is as follows: after fermentation induction of recombinant engineered bacteria to express tandem proteins in the form of inclusion bodies, the bacteria are broken to collect the inclusion bodies, and after denaturation, renaturation and other steps, the soluble tandemly expressed semaglutide intermediates are obtained after enzymatic digestion with KEX2 enzyme and carboxypeptidase B. In this process, surfactants such as sodium dodecyl sulfate are introduced.

[0019] Preferably, in the filtration process described in step 1, the pore size of the filter membrane selected is 0.22 or 0.45 μm, preferably 0.22 μm.

[0020] Reaction principle:

[0021] (1) When surfactants are added (mainly ionic surfactants in this article), the presence of surfactants will reduce the hydrophobic interaction and ionize anions in the solution, thereby affecting the binding and elution of hydrophobic fillers and the binding and elution of samples on anionic fillers.

[0022] (2) PolyRP polymer filler uses highly cross-linked polystyrene / divinylbenzene (PS / DVB) as the matrix, which has strong rigidity and contains phenyl functional groups in the stationary phase. By utilizing the strong hydrophobic properties of the matrix skeleton itself, it can be directly used as a reverse phase separation filler for separation and purification.

[0023] (3) Poly-RP filler with PS / DVB as the matrix has a relatively wide range of alkali resistance. Under the same alkaline conditions, the silica-based filler will be ionized due to the free silanol group, resulting in a more complicated purification force; while the PS / DVB matrix has no ionization and the force is relatively simple. In the purification process of this sample, it can achieve a better purification effect.

[0024] (4) When a surfactant is added, the hydrophobic force of the hydrophobic filler is weakened, the binding of the anionic filler is interfered by the anions ionized by the surfactant, and the free silanols of the silica gel reverse phase filler are ionized. These factors will affect the relevant purification results. However, the Poly-RP filler with PS / DVB as the matrix does not have the above influencing factors, so it can achieve better purification results.

[0025] Beneficial effects: Compared with the prior art, the present invention has the following significant beneficial effects: (1) The reverse phase filler PolyRP is used as the stationary phase to provide a variety of optional schemes for the purification method of semaglutide containing surfactants; (2) The reverse phase filler with PS / DVB as the matrix is ​​used as the stationary phase, and the purification can be completed without combining with the anion capture process, which simplifies the process steps and improves the sample purity and recovery rate; (3) The reverse phase filler with PS / DVB matrix has a greatly reduced production cost compared with the reverse phase filler with silica gel matrix bonded with octyl or octadecyl; (4) This scheme only needs one purification to increase the purity of the original semaglutide intermediate containing surfactants of about 60% to 95-99% and the recovery rate of 95-100%. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 This is a purity analysis chart of the crude product of Example 1;

[0027] Figure 2 This is a purity analysis diagram of the purified sample in Example 1;

[0028] Figure 3 for Figure 2 A partial enlarged view of the middle A area;

[0029] Figure 4 This is a purity analysis diagram of the purified sample in Example 2;

[0030] Figure 5 This is the purity analysis diagram of the crude product of Comparative Example 1;

[0031] Figure 6 This is a purity analysis diagram of the purified sample of Comparative Example 1;

[0032] Figure 7 for Figure 6 A partial enlarged view of the middle A area;

[0033] Figure 8 This is the purity analysis diagram of the purified sample of Comparative Example 2;

[0034] Fig. 9 This is a purity analysis chart of the purified sample in Comparative Example 3. DETAILED DESCRIPTION

[0035] The technical solution of the present invention is further described below in conjunction with embodiments.

[0036] Example 1

[0037] The method for purifying the semaglutide intermediate with a surfactant of the present invention comprises the following steps:

[0038] Semaglutide inclusion body fermentation expression solution after enzyme digestion and purification

[0039] Sample Information:

[0040] After the recombinant engineered bacteria were used to induce the expression of tandem proteins in the form of inclusion bodies, the bacteria were broken to collect the inclusion bodies, and after denaturation and renaturation, the soluble tandemly expressed semaglutide intermediates were obtained after digestion with KEX2 enzyme and carboxypeptidase B. In this process, surfactants such as SDS (sodium dodecyl sulfate) were introduced.

[0041] Step 1: Sample preparation

[0042] The crude semaglutide intermediate was taken and the sample was filtered through a 0.22 μm filter membrane to obtain a filtrate.

[0043] Step 2: Mobile phase preparation

[0044] Mobile phase A: Weigh 1.89 g of ammonium formate, dissolve it in 800 mL of pure water, add pure water to make up to 1 L, adjust the pH to 7.5 with formic acid solution and ammonium formate solution to obtain a solution of 30 mM ammonium formate, pH 7.5.

[0045] Mobile phase B: pure acetonitrile

[0046] Step 3: Column Preparation

[0047] PolyRP-300 provided by Suzhou Saifen Technology Co., Ltd. was used as filler. The filler is based on highly cross-linked polystyrene / divinylbenzene (PS / DVB) material, with a phenyl functional group-containing substance as the stationary phase, a particle size of 10 μm, and a pore size of

[0048] Install a chromatography column as needed.

[0049] For example, the specifications of the chromatography column used in this embodiment are: 4.6 mm×250 mm, 1CV=4.15 mL.

[0050] Step 4: Experimental process

[0051] UV 280nm was selected as the monitoring signal, and the flow rate was calculated based on a residence time of 6 min, which was approximately 0.7 min / mL.

[0052] 90% A + 10% B was used as the balancing liquid to balance the chromatography column in advance until the pressure curve and UV curve were balanced and the UV curve returned to zero.

[0053] The filtrate obtained in step 1 was loaded at a loading of 10 mg / mL (calculated based on the target compound).

[0054] 90% A + 10% B was used as the equilibration liquid to post-equilibrate the chromatography column, and the running volume was about 2 to 3 column volumes. The elution was performed according to the elution gradient in Table 1, the slope of the gradient elution was 5 to 10 minutes, the step was 1%, and the time taken for the elution gradient from 20% to 40% was 100 to 200 minutes.

[0055] Table 1 Elution conditions in Example 1

[0056] Time (min) Mobile phase A (%) Mobile phase B (%) 0 90 10 10 90 10 30 80 20 110 72 28

[0057] During the elution process, fraction solutions were collected with signal values ​​ranging from rising to 500 mAU to falling to 500 mAU under monitoring at 280 nm.

[0058] After the elution is completed, the column is regenerated and cleaned with 20% A + 80% B solution, and the running volume is about 2 to 3 column volumes.

[0059] Step 5: Testing plan

[0060] Detection mobile phase: A: 0.1% TFA / pure water; B: 0.1% TFA / acetonitrile.

[0061] Detection column: Sepax Bio-C18, particle size 5μm, pore size The packing material is 4.6×250mm.

[0062] Detection wavelength: 214 nm, flow rate: 1 mL / min, sample loading: 10-20 μg.

[0063] After injection, elution analysis was performed according to the conditions in Table 2:

[0064] Table 2 Conditions for elution analysis

[0065]

[0066]

[0067] Crude product purity analysis see Figure 1 ,according to Figure 1 It can be seen that there are more impurities in the crude product, so that the purity of the crude product is not high.

[0068] Step 6: Combine samples and analyze

[0069] The fraction solution with a purity greater than 95% in the analysis result of step 5 is selected, and the samples are combined to test the purity and recovery rate. The obtained combined sample is the purified sample of the semaglutide intermediate.

[0070] Purity analysis of the combined samples is shown in Figure 2-3 It can be seen that there are few impurities in the purified sample and the sample purity is high. The liquid phase integration of the purity data yields a value of 98.829%.

[0071] The sample recovery was calculated using the peak area and volume obtained from the analytical chromatogram and the peak area and volume of the crude product.

[0072] The experimental results are shown in Table 3.

[0073] Table 3 Experimental results of Example 1

[0074] Sample purity Elution purity Recovery rate 59.240 98.829% 98.32%

[0075] Example 2

[0076] The same parts as Example 1 will not be repeated here, except that the elution conditions in step 4 are different.

[0077] Elution was performed according to the elution gradient in Table 4:

[0078] Table 4 Elution conditions in Example 2

[0079] Time (min) Mobile phase A (%) Mobile phase B (%) 0 90 10 10 90 10 20 80 20 120 60 40

[0080] Purity analysis of combined samples Figure 4 ,according to Figure 4 It can be seen that there are few impurities in the purified sample and the sample purity is high. The purity data is integrated by liquid phase and the value is 96.632%.

[0081] The experimental results are shown in Table 3.

[0082] Table 5 Experimental results of Example 2

[0083] Sample purity Elution purity Recovery rate 59.380 96.632% 98.57%

[0084] Comparative Example 1

[0085] The similarities between this comparative example and Example 1 are not repeated here, except that a different chromatography column is used in step 3.

[0086] BR-C18(2) provided by Suzhou Saifen Technology Co., Ltd. was used as the filler. The filler is based on silica gel and bonded with octadecyl carbon chain as the stationary phase. The particle size is 8 μm and the pore size is

[0087] The experimental results are shown in Table 6.

[0088] Table 6 Experimental results of comparative example 1

[0089] Sample purity Elution purity Recovery rate 59.380 96.802% 93.8%

[0090] Purity analysis of purified samples Figure 6-7 shown.

[0091] According to the comparison of the experimental results in Table 3 and Table 6, the purity and recovery rate of the purified sample are both high when the reverse phase filler PolyRP-300 with PS / DVB as the matrix is ​​used as the stationary phase. In the technical field, it is technically difficult to increase the sample purity from 96.8% to 98.8% and the recovery rate from 93.8% to 98.3%. Comparison of the eluate sample analysis chart of Example 1 and Comparative Example 1 (i.e. Figure 2-3 and Figure 6-7 ), it can be found that the eluate sample of comparative example 1 has a relatively large impurity that has not been removed at about 14 minutes. During the purification process, some key impurities that are difficult to remove will appear. The presence of such impurities is often an important reason why the purity of the purified sample cannot be improved. When the reverse phase filler of the PS / DVB matrix is ​​used to purify the semaglutide intermediate, most of the impurities can be removed, thereby achieving an improvement in purity.

[0092] Comparative Example 2 Hydrophobic Capture Process

[0093] Filler: Generik MC60-HIC Butyl (Suzhou Saifen Technology Co., Ltd.)

[0094] Chromatography column specifications: 6.6*150mm, CV=5.132mL

[0095] Sample processing:

[0096] After semaglutide is expressed in the form of inclusion bodies, an intermediate is obtained after enzymatic cleavage, and a surfactant is added to maintain the stability of the sample to obtain a crude semaglutide intermediate with a tested purity of less than 60%.

[0097] The crude semaglutide intermediate was taken and diluted with 20 mM Tris-HCl, 2 M NaCl, pH 9.0 to a NaCl concentration of 500 mM. At the same time, the pH of the sample was adjusted to 8.5 ± 0.05 with 2 M Tris and 50% HCl solution.

[0098] According to the requirements for the chromatography column specifications, a Generik MC60-HIC Butyl chromatography column was installed.

[0099] Purification was performed according to the steps shown in Table 7.

[0100] Table 7 Purification steps of Comparative Example 2

[0101]

[0102]

[0103] The experimental results are shown in Table 8.

[0104] Table 8 Experimental results of comparative example 2

[0105] sample Volume ml purity% Yield % Loading 85 59.089 N / A Flow Through 90 10.203 2.28 Wash 46.04 72.605 19.16 Elution 29.93 90.141 82.85

[0106] The liquid phase analysis of the purified sample is shown in Figure 8 shown.

[0107] Comparative Example 3 Anion Capture Process

[0108] Filler: Proteomix POR30-Q (Suzhou Saifen Technology Co., Ltd.)

[0109] Chromatography column specifications: 6.6*150mm, CV=5.132mL

[0110] Sample processing:

[0111] After semaglutide is expressed in the form of inclusion bodies, an intermediate is obtained after enzymatic cleavage, and a surfactant is added to maintain the stability of the sample to obtain a crude semaglutide intermediate with a tested purity of less than 60%.

[0112] Take the crude semaglutide intermediate, adjust the sample conductivity to less than 5 mS / cm with pure water, and adjust the sample pH to 8.5±0.05 with 2M Tris and 50% HCl solution.

[0113] According to the requirements for the chromatography column specifications, install a Proteomix POR30-Q chromatography column.

[0114] Purification was performed according to the steps shown in Table 9.

[0115] Table 9 Purification steps of Comparative Example 3

[0116]

[0117]

[0118] Experimental results: The sample purity was 89.26% and the recovery rate was 83.07%.

[0119] The liquid phase analysis of the purified sample is shown in Fig. 9 shown.

[0120] After purification according to the existing scheme, it was found that the purity of the sample obtained by the hydrophobic-related purification scheme was only about 90%, and the recovery rate was only 82.85%, which was lower than 90% (i.e., Comparative Example 2); the purity of the sample obtained by the anion-related purification scheme was less than 90%, and the recovery rate was 83.07% (i.e., Comparative Example 3). In general, the purity and recovery rate of the samples obtained by the hydrophobic capture process and the anion capture process were not high.

[0121] When the surfactant was removed and the semaglutide intermediate was used for testing, it was found that when the salt concentration of the semaglutide intermediate was 500mM, the sample became turbid after being left for 1 hour. Liquid phase detection revealed that this was due to precipitation of the intermediate, that is, under the salt concentration of normal purification, the stability of the sample was affected, resulting in the inability to complete the hydrophobic chromatography loading process.

[0122] In general, when no surfactant was added to the semaglutide intermediate expressed in inclusion bodies, the sample was not stable enough to complete chromatographic purification due to the high sample concentration and complex reagents of variable refolding; after the addition of surfactant, neither ionic nor hydrophobic chromatography schemes could achieve a purification effect with high purity and high recovery rate.

[0123] The method for purifying a semaglutide intermediate with a surfactant described in the present invention uses a reverse phase filler with a highly cross-linked polystyrene / divinylbenzene (PS / DVB) material as a matrix as a stationary phase, simplifies the process steps, and improves sample purity and recovery rate.

Claims

1. A method for purifying a semaglutide intermediate containing a surfactant, characterized in that: The steps include: Step 1: filtering the crude semaglutide intermediate to obtain a filtrate; Step 2: Take the filtrate obtained in step 1, use the reverse phase filler as the stationary phase, ammonium formate solution as the mobile phase A, and acetonitrile as the mobile phase B, perform gradient elution on the filtrate, and collect the fraction solution; Step 3: Conducting purity analysis on the fraction solution in step 2; Step 4: Combine the fraction solutions with a purity greater than 95% in step 3, and test the purity and recovery rate. The resulting combined sample is the purified sample of the semaglutide intermediate.

2. The method for purifying a semaglutide intermediate with a surfactant according to claim 1, characterized in that: The reverse phase filler described in step 2 is based on a highly cross-linked polystyrene / divinylbenzene material.

3. The method for purifying a semaglutide intermediate with a surfactant according to claim 1, characterized in that: The particle size of the reverse phase filler in step 2 is 10 μm and the pore size is 4. The method for purifying a semaglutide intermediate with a surfactant according to claim 1, characterized in that: The molar concentration of the ammonium formate solution in step 2 is 20-50 mmol / L, and the pH is 7.0-8.

0.

5. The method for purifying a semaglutide intermediate with a surfactant according to claim 4, characterized in that: The molar concentration of the ammonium formate solution in step 2 is 30 mmol / L, and the pH is 7.

5.

6. The method for purifying a semaglutide intermediate with a surfactant according to claim 1, characterized in that: The crude product described in step 1 is prepared as follows: after inducing the expression of tandem proteins in the form of inclusion bodies by fermentation with recombinant engineered bacteria, the bacteria are broken to collect the inclusion bodies, and after denaturation, renaturation and other steps, a soluble tandemly expressed semaglutide intermediate is obtained after enzymatic digestion with KEX2 enzyme and carboxypeptidase B; in this process, SDS (sodium dodecyl sulfate) is introduced as a surfactant.

7. The method for purifying a semaglutide intermediate with a surfactant according to claim 1, characterized in that: The gradient elution described in step 2 has a slope of 5 to 10 minutes, a step of 1%, and a time taken for a 20-40% gradient of 100 to 200 minutes.

8. The method for purifying a semaglutide intermediate with a surfactant according to claim 1, characterized in that: In the collected fractions described in step 2, the collection range is from the time when the signal value rises to 500 mAU to the time when the signal value drops to 500 mAU under monitoring at 280 nm.

9. The method for purifying a semaglutide intermediate with a surfactant according to claim 1, characterized in that: In the filtration process described in step 1, the pore size of the filter membrane selected is 0.22 μm or 0.45 μm.

10. The method for purifying a semaglutide intermediate with a surfactant according to claim 9, characterized in that: In the filtration process described in step 1, the pore size of the filter membrane selected is 0.22 μm.